US Stocks Movement: Fabrinet Plummets on October 22 as Target Price Is Lowered and Continuous Decline Persists
Bitget异动解读2026/10/22 14:31Fabrinet October 22 Price Drop Analysis
Keywords: Target Price Downgrade, Consecutive Declines
1. On October 22, Susquehanna analysts maintained an “Outperform” rating on Fabrinet but lowered the target price from $850 to $600. The significant target price downgrade has reduced the market's reference level for its valuation.
2. On October 22, Fabrinet’s share price continued its downward trend, dropping to $358.38 during trading hours. Reports indicate it is entering its longest streak of consecutive declines, with the persistent weakness in technical indicators increasing short-term selling pressure.
(Disclaimer: This content is generated by AI based on publicly available information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
SpaceX says any potential merger with Tesla still requires further approval
Moderna plunges by as much as 26%, setting a record for the biggest single-day drop! Melanoma vaccine data leaked early, results fall short of expectations
Clinical trial data from phase 3 of the personalized melanoma vaccine jointly developed by Moderna and Merck was unexpectedly leaked ahead of schedule. The data showed a 42% reduction in cancer recurrence risk and a 38% reduction in risk of distant metastasis. These results fell short of market expectations, as an earlier study had shown the combination therapy could reduce recurrence risk by 49% and distant metastasis risk by 59%. Moderna's stock price plunged as much as 26% intraday, later rebounded partially, and ultimately closed down 17.6%.
SpaceX stated that the Tesla merger requires Elon Musk's approval.
Crypto prices
More
